on the department to ensure the timely release of finalised guidelines introducing short-course TPT regimens.
According to Churchyard, they have done a number of modelled cost-effectiveness studies. “In South Africa, 3HP is cost-effective, and that’s largely because of our high costs of routine care within the country. In South Africa, there are clear cost-effectiveness benefits.” “The guideline development process for South Africa started in early 2019. We thought that South Africa being the country that always excels at these things… would move fast, but we are still waiting for those guidelines to be released,” says Mabote.
“A lot of provinces have already received training through the Impaact4TB project… by Aurum and other partners,” says Mabote. She adds that the health department is rolling out more training of healthcare workers and civil society has started doing work to generate community demand for 3HP. “I think we need to do a lot more, but at least the work is underway,” says Mabote.
that while the department has previously procured Sanofi’s rifapentine for use in pilot sites, the health department expects to begin procuring Macleod’s fixed-dose combination 3HP tablets if they are available at an affordable price. Mohale says that “pricing for public sector procurement is pending finalisation,” and notes that once a price is available, the National Essential Medicines List Committee will review whether rifapentine can be included on the national essential medicines list.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Tailor-made treatment ensures your genes fit your medsPrecision medicine, which targets the individual rather than offering a one-size-fits-all approach, is sweeping the world and has finally reached SA.
Source: SundayTimesZA - 🏆 47. / 51 Read more »
Source: Moneyweb - 🏆 5. / 77 Read more »